Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Releases Quarterly Earnings Results, Misses Expectations By $0.74 EPS

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) announced its earnings results on Thursday. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.74), Yahoo Finance reports. Calliditas Therapeutics AB (publ) had a negative return on equity of 104.47% and a negative net margin of 38.72%.

Calliditas Therapeutics AB (publ) Trading Up 0.2 %

CALT opened at $21.76 on Friday. The company has a debt-to-equity ratio of 2.89, a quick ratio of 3.08 and a current ratio of 3.13. The stock’s 50 day moving average price is $20.60 and its 200-day moving average price is $21.11. Calliditas Therapeutics AB has a one year low of $15.25 and a one year high of $29.30. The stock has a market cap of $648.23 million, a price-to-earnings ratio of -13.27 and a beta of 1.50.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reduced their target price on shares of Calliditas Therapeutics AB (publ) from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Friday.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.